Effect of treatment with beta-agonists on tissue and urinary taurine levels in rats. Mechanism and implications for protection.
Administration of clenbuterol to rats in the drinking water over a four day period increased incorporation of [3H]leucine into muscle protein but did not result in an increase in body or muscle weight. However, both urinary and liver taurine were significantly reduced at the highest dose of clenbuterol (2 mg.kg-1.day-1). Salbutamol also reduced urinary levels of taurine in both rats and humans. The reduction in the body pool of taurine caused by beta-agonists may be of concern as taurine has been shown to have protective properties.
Department of Toxicology, School of Pharmacy, London, United Kingdom.
C J
CJ
Waterfield
F
F
Carvalho
J A
JA
Timbrell
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000420:Albuterol / Q000494:pharmacology*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002976:Clenbuterol / Q000494:pharmacology*; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007930:Leucine / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000096:biosynthesis; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012044:Regression Analysis; D013654:Taurine / Q000378:metabolism* / Q000652:urine
D000318:Adrenergic beta-Agonists; D007527:Isoenzymes; D009124:Muscle Proteins; D013654:Taurine; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D007930:Leucine; D000420:Albuterol; D002976:Clenbuterol